Device Trial Radar · NCT03758521
Natural History Study of Patients With Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency
Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
Jan 15, 2019
Primary completion
May 31, 2029
Study completion Jun 2029
Sponsor
- Lead sponsor
- Boston Children's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Washington State University; University of South Florida; University Hospital Heidelberg; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- First posted
- Nov 29, 2018
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Succinic Semialdehyde Dehydrogenase deficiency (SSADHD) is a rare autosomal recessive disease that interferes with the catabolism of the major inhibitory neurotransmitter gamma-amino butyric acid (GABA) and furthermore leads to accumulation of various potential toxic metabolites, most prominently gamma hydroxybutyric acid (GHB). Current research indicates that there is developmental delay and significant neurophysiological and biochemical alterations in SSADHD patients, but whether disease presentation varies with age is not known. The investigators propose to determine the natural course of the clinical presentation of SSADHD; to determine the natural course of neurophysiological and biochemical indices known to be altered in SSADHD; and to identify neurophysiological and biochemical predictors of clinical severity. The overall objective is to define the natural course of the clinical, neurophysiological and biochemical spectrum of SSADHD. Secondary objectives include the identification of biomarkers that correlate with disease phenotype and predict clinical outcomes, and the creation of an international SSADHD data repository for future investigation of pathogenesis and therapy.
Conditions
- Succinic Semialdehyde Dehydrogenase Deficiency
Interventions
Transcranial magnetic stimulation (TMS)Device
Transcranial magnetic stimulation (TMS) is a method for noninvasive electrical cortical stimulation, where small intracranial currents are generated by a powerful, fluctuating, extracranial magnetic field. TMS is unique in its capacity for experimental, diagnostic, and therapeutic utility. Single pulse (spTMS) and paired-pulse TMS (ppTMS) have been used extensively to study, measure, and modulate cortical excitability and plasticity.
Magnetic resonance imaging (MRI)Device
These will be outpatient MRI studies that are planned without sedation. Subjects enrolled at BCH will undergo brain MRI, including volumetric MRI, MRS, and diffusion tensor imaging (DTI). The data will help define the natural history of brain volume, brain myelination and spectroscopic (e.g. GABA) abnormalities.
Electroencephalogram (EEG)Device
These will be outpatient EEG recordings that span 20-60 minutes and done without sedation. Recordings will be performed using electrode locations specified by the international 10-20 system for standard clinical practice.
Bio-specimen CollectionProcedure
Bio-specimen collection will include blood, urine, saliva, hair, stool, and a skin biopsy. Blood, urine, saliva, blood spots, and hair samples will also be banked for to-be-determined (TBD) studies.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Severity ScoreTime frame: 5 Years
- Biochemical - GABA measurementTime frame: 5 Years
- Biochemical - GHB measurementTime frame: 5 Years
1 more outcomes with a free account
Locations
4 sites in 4 countries. Site status is shown where the registry gives one.
Boston Children's Hospital
Boston, Massachusetts · Recruiting
University Children's Hospital
Heidelberg, Heidelberg, Germany · Recruiting
Sant Joan de Deu Hospital Barcelona
Barcelona, Spain · Active not recruiting
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.